Bionor Pharma Announces that the Combination of Vacc-4x + Revlimid® is Well Tolerated and Increases CD4 Counts in People Living with HIV
(Oslo, Norway, 17 November 2014) Bionor Pharma ASA (OSE:BIONOR) announces the results from the Vacc-4x + Revlimid (lenalidomide) study also known as the “Boost & Kill” study. The Phase II trial was an exploratory double-blind placebo controlled immunogenicity study of Vacc-4x + Revlimid versus Vacc-4x in HIV subjects on ART (HIV standard of care treatment). …
Bionor Pharma’s REDUC trial – Highlight of the 2014 AIDS conference
At the 2014 AIDS conference in Melbourne the results from Part A for Bionor Pharma’s REDUC trial was one of the key events and a substantial media coverage followed the presentation of the data. The trial combines Bionor Pharma’s therapeutic vaccine candidate Vacc-4x with the cancer drug Romidepsin (Celgene Corp) and is conducted in collaboration …
First Evidence that Romidepsin “Kicks” HIV out of Reservoirs
Results from Part A of Bionor Pharma’s REDUC study Presented at the 2014 AIDS Conference and IAS’ HIV Cure Symposium (Oslo, Norway, 22 July 2014) Bionor Pharma ASA (OSE: BIONOR) announces that data from part A of the REDUC study has been presented at the 2014 International AIDS Conference in Melbourne, Australia. The topline results …
Bionor Pharma Presents Data at the AIDS 2014 Conference on Potential Biomarker for Reduction of Viral Load Identified for Vacc-4x
(Oslo, Norway, 18 July 2014) Bionor Pharma ASA (OSE: BIONOR) announces that results of the ad hoc, subset analysis of the large Phase II clinical study of therapeutic HIV vaccine candidate Vacc-4x – which identified C5/gp41 antibody levels as a potential biomarker for improved response to Vacc-4x – were presented today as a poster at the AIDS …
Bionor Pharma Announces Successful Completion of Part A of REDUC Study; First Evidence that Romidepsin “Kicks” HIV out of Reservoirs
•HDAC inhibitor (HDACi) Istodax® (romidepsin) successfully reactivated (“kick”) HIV in patients •Treatment of Istodax® was safe and well tolerated •Part B of the REDUC study to enroll patients in Q2 2014 (Oslo, Norway, 12 May 2014) Bionor Pharma ASA (OSE: BIONOR) announces that the part A of the REDUC study has successfully completed. The objective …
Bionor Pharma Announces Completion of Enrollment of Part A of REDUC trial
(Oslo 1 April, 2014) Bionor Pharma ASA (OSE: BIONOR) announced today the completion of enrollment of patients for part A of the Phase I/II REDUC study. The trial combines Bionor Pharma’s lead vaccine candidate Vacc-4x and the HDAC inhibitor Istodax® (romidepsin). Part A of the study will establish the optimal dose of Istodax in a …
Reboost Data Reconfirms 2010 Study
Bionor Pharma’s Phase II Therapeutic HIV Vaccine Vacc-4x: Reboost Data Reconfirms 2010 Study (Oslo, Norway, 28 March 2014) Bionor Pharma ASA (OSE: BIONOR) announces the results from the Vacc-4x Phase II Reboost trial. The trial explored the effects of Vacc-4x revaccination or reboosting of HIV infected patients that participated in the large 2010 Phase II …
Bionor Pharma Announces Approval of REDUC Trial
Bionor Pharma ASA announces that the Company has received approval from the Danish Regulatory Agency for its REDUC trial. The REDUC trial is a combination of Bionor Pharma’s lead vaccine candidate Vacc-4x and the Histone DeAcetlyase inhibitor (HDACi) Istodax®(romidepsin). Bionor Pharma further announces that the Company today has entered into a Supply Agreement with Celgene …
Positive Results from Bionor Pharma’s vaccine Vacc-C5 Phase I, First Time in Man trial
(Oslo, Norway, 24 February 2014) Bionor Pharma ASA (OSE: BIONOR) announces that results from its Phase I, first in man, trial of Vacc-C5. The trial met its primary endpoint which was safety. The trial also demonstrated that Vacc-C5 was able to generate C5 antibodies with effect of boosting, particularly in the top dose group. Increase …
Bionor Pharma’s Phase II Vacc-4x Data Published in The Lancet Infectious Diseases
Therapeutic HIV Vaccine, Vacc-4x, Reduced Viral Load in HIV Patients Compared to Placebo in Largest Randomized, Placebo-controlled Study of its Kind in Recent History, Published in Lancet Infectious Diseases To access the article click here. For comment on the Vacc-4x trial and therapeutic vaccines research published in the Lancet Infectious Diseases click here. (Oslo, Norway, 11 February …